A Lilly statement said, "We will continue to take action to stop these illegal actors and urgently call on regulators and law ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

The Trump administration rejected a proposed rule to allow Medicare to cover blockbuster obesity drugs for weight loss alone ...

Amy Schumer shared she quit Wegovy due to side effects like nausea but was "having a really good experience" with Mounjaro, ...

Eli Lilly has launched Mounjaro in India, a once-weekly injection targeting both type 2 diabetes and obesity, priced at Rs 3,500 for a 2.5mg dose. This dual-action drug stimulates two key hormone ...

The drugmaker accuses Premier Weight Loss of risking patients' health by selling altered, unsterile versions of its ...

Eli Lilly has launched weight-loss drug Mounjaro in India, priced at Rs 3,500 per injection for a 2.5mg dose. Will high costs ...

Cristina Arias / Cover / Getty Images Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly ... and Wegovy and Lilly's Mounjaro and Zepbound.

In that time, Eli Lilly has seen explosive growth, largely due to its blockbuster diabetes and weight-loss drugs, Mounjaro and Zepbound. Mounjaro brought in $11.5 billion in sales in 2024 ...

(Reuters) - Eli Lilly plans to launch its blockbuster diabetes ... In February last year, CEO David Ricks told Reuters that Lilly expects to launch Mounjaro in India as early as 2025. Mounjaro, ...

March 10 (Reuters) - Eli Lilly (LLY.N), opens new tab ... In February last year, CEO David Ricks told Reuters that Lilly expects to launch Mounjaro in India as early as 2025.